Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.

Research output: Contribution to journalJournal articleResearch

  • J K Madsen
  • J F Hansen
View graph of relations
The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8%) and other severe diseases (38.9%).
Translated title of the contributionMortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.
Original languageEnglish
JournalEuropean Heart Journal
Volume14
Issue number3
Pages (from-to)377-379
Number of pages3
ISSN0195-668X
Publication statusPublished - 1993

ID: 32553187